alvespimycin

also known as 17-DMAG · 17-dimethylaminoethylamino-17-demethoxygeldanamycin · 17-dmag hcl · Alvespimicina · Alvespimycin hcl · alvespimycin hydrochloride · Alvespimycine · BMS-826476 · +2 more

Small molecule

Developed for: breast cancer · cancer of unknown primary site · chronic lymphocytic leukemia/small lymphocytic lymphoma · adenoid cystic carcinoma · adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · Burkitt lymphoma
+34 more
· diffuse large B-cell lymphoma · esthesioneuroblastoma · female breast carcinoma · gastric carcinoma · Hodgkins lymphoma · hypopharynx squamous cell carcinoma · intraocular lymphoma · intraoral basal cell carcinoma · inverted papilloma · larynx verrucous carcinoma · lymphoepithelial-like carcinoma · lymphoma · male breast carcinoma · malignant colon neoplasm · MALT lymphoma · mantle cell lymphoma · melanoma · metastatic squamous cell carcinoma · mycosis fungoides and variants · nasal cavity and paranasal sinus lethal midline granuloma · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · nodal marginal zone B-cell lymphoma · oral cavity mucoepidermoid carcinoma · oropharynx squamous cell carcinoma · ovarian carcinoma · prolymphocytic leukemia · prostate carcinoma · renal cell carcinoma · salivary gland cancer · small intestine cancer · splenic marginal zone lymphoma · verrucous carcinoma of oral cavity · Waldenstrom macroglobulinemia
Investigated by: National Cancer Institute (NCI) · Bristol-Myers Squibb · Institute of Cancer Research, United Kingdom · National Institutes of Health Clinical Center (CC)

Trials 7 · a red edge is where a trial was stopped

today NCT01126502 · Ph 1 NCT00780000 · Ph 2 NCT00803556 · Ph 1 NCT00248521 · Ph 1 NCT00089362 · Ph 1 NCT00089271 · Ph 1 NCT00088868 · Ph 1

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT01126502	May 2010 → Jun 2012	chronic lymphocytic leukemia/small lymphocytic lymphoma, prolymphocytic leukemia	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT00803556	Jan 2006 → Aug 2009	breast cancer	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00248521	Oct 2005 → Jan 2007	cancer of unknown primary site	Institute of Cancer Research, United Kingdom	Unknown	No outcome recorded
Phase 1	NCT00089362	Jul 2004 → Jan 2008	adenoid cystic carcinoma, cancer of unknown primary site, esthesioneuroblastoma, female breast carcinoma +20	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00089271	Jul 2004 → Jun 2010	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +10	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00088868	Jun 2004 → Mar 2010	lymphoma, small intestine cancer	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT00780000	Apr → Jun 2008	breast cancer	Bristol-Myers Squibb	Terminated	No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

Field	Value	Cited text
Known as	alvespimycin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00248521 ↗ 4 NCT00089271 ↗ NCT00803556 ↗ NCT00780000 ↗ NCT01126502 ↗
Known as	17-dimethylaminoethylamino-17-demethoxygeldanamycin	“A Cancer Research UK Phase I trial to evaluate the safety, tolerability and pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) given as a once...” NCT00248521 ↗ 1 “17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)” NCT00088868 ↗
Known as	17-DMAG	“A Cancer Research UK Phase I trial to evaluate the safety, tolerability and pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) given as a once...” NCT00248521 ↗ 2 “A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell...” NCT01126502 ↗ “17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)” NCT00088868 ↗
Known as	17-dmag hcl	ChEMBL registry synonym — accepted as the source's own label CHEMBL383824 ↗
Known as	Alvespimicina	ChEMBL registry synonym — accepted as the source's own label CHEMBL383824 ↗
Known as	Alvespimycin hcl	ChEMBL registry synonym — accepted as the source's own label CHEMBL383824 ↗
Known as	alvespimycin hydrochloride	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00089362 ↗
Known as	Alvespimycine	ChEMBL registry synonym — accepted as the source's own label CHEMBL383824 ↗
Known as	BMS-826476	ChEMBL registry synonym — accepted as the source's own label CHEMBL383824 ↗
Known as	KOS-1022	“Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer” NCT00780000 ↗
Known as	NSC-707545	ChEMBL registry synonym — accepted as the source's own label CHEMBL383824 ↗
Modality	Small molecule	— CHEMBL383824 ↗
Route	Intravenous	“17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-2 hour” NCT00088868 ↗